Honoured to receive the #Dementia Advocates’ Award. Means so much to me that the importance of our research endeavors are recognised by the community we are trying to help.

Excited to be awarded the Royce Simmons Foundation Mid-Career Research Fellowship by @DementiaAus to continue my work on #dementia.

Why many Aβ-positive cognitively unimpaired individuals do not develop downstream tau pathology? Our new study led by @BellaverBruna published in @NatureMedicine shows that looking at reactive astrocytes may help start solving this question.

https://t.co/pqjAMe4wGm

Thank you @gabyrogers and @9NewsAUS for covering our research 🧠🔬 If you’re interested in participating, please call us at 0493499035 or email us at au.arrow@mq.edu.au https://t.co/G7rdS7YIGl

#LestWeForgetIndia🇮🇳 the gallantry of Cdr Nishant Singh- made the supreme sacrifice on 26 November 2020; awarded the #NauSenaMedal (Posthumous) on #RepublicDay2023 26 January 2023 by the President of India Remember the #IndianBrave and his service to Nation, always

🙏Equally excited to share plasma glial fibrillary acidic protein (#GFAP) in #DIAN! 👉 see: https://t.co/EcPMyE5Xvw @alzdemjournals 👉 or go for the summary below by my dear co-author @PratishthaChat7 @AlzheimerAms @Alz_onderzoek @AmsNeuroscience #stichtingdioraphte

(6/6) Plasma and serum GFAP carried similar information in ADAD. Cerebrospinal fluid GFAP had a weaker correlation with blood-based GFAP.

(5/6) Higher plasma GFAP is associated with faster disease progression

(4/6) Plasma GFAP increased with clinical severity

(3/6) Plasma GFAP was associated with abnormal beta-amyloid accumulation in ADAD mutation carriers

(2/6) Higher plasma GFAP levels appeared a decade before expected symptom onset. These higher levels occurred after abnormal beta-amyloid accumulation, but prior to neurodegeneration and cognitive decline.

(1/6) Excited that our paper on plasma glial fibrillary acidic protein (#GFAP) in dominantly inherited #AlzheimersDisease is now out👉 https://t.co/fgWHENqkBr. @alzdemjournals. 🙏Many thanks @LisaVermunt @BrianGordon81 @RalphNMartins1 @CharlotteTeuni1 and all collaborators!

USP11 removes ubiquitin from tau, allowing it to be acetylated and increasing its tendency to aggregate. Women have three times more USP11 than men. @cwru

This needs to be shared and discussed. A ‘gig economy’ is affecting the Australian medical research sector and will have long term effects

(4/4) A big thank you to all involved🙏 @RalphNMartins1 @CoMBAT_AD @MQMedicalSchool @EdithCowanUni @UniMelb @ehealthresearch @PittTweet @Austin_Health @MurdochUni @AustAlzResearch @TheFlorey @Cogstate

(3/4) Aβ, p-tau181, GFAP and NFL were associated with faster future cognitive decline Aβ, p-tau181 and GFAP were associated with faster future Aβ-PET load increase Longitudinally over 36m these blood biomarkers changed at a faster rate in MCI/ AD compared to healthy older adults

(2/4) We found discriminative performance of p-tau181 for AD, for preclinical to dementia stages, was ≥ Aβ/ GFAP/ NFL However, a panel including Aβ, p-tau181 and GFAP had higher discriminative performance for AD, for preclinical to dementia stages, with 85-95% accuracy

(1/4) Happy to announce that our paper on head-to-head comparison of #AlzheimersDisease #bloodbiomarkers, Aβ (42/40 ratio), p-tau181, GFAP, NFL, for preclinical to dementia stages, is now out! 👉 https://t.co/VIxFs9sZgN. @alzdemjournals

Thank you @RalphNMartins1, the @CoMBAT_AD and the scientists at Macquarie, ECU and UWA for hosting me virtually! I had a great time and hope I get a chance to visit you all again as I did in 2019!